BioCentury | Aug 13, 2020
Management Tracks

NHC’s Boutin to head patient advocacy at Novartis; plus changes at Moderna, PIC, Atea, Terns, NBE and Omega

...of R&D strategy at Sanofi (Euronext:SAN; NASDAQ:SNY), and also previously launched and led the pharma’s Sanofi Sunrise...
BioCentury | Apr 28, 2018
Strategy

The outsiders

As he retires from Sanofi, Elias Zerhouni has advice for the biopharma industry: the traditional executive mold must be expanded. On April 24, Sanofi announced Zerhouni would retire on June 30 and that John Reed,...
BioCentury | Aug 17, 2017
Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
BioCentury | Jun 9, 2016
Strategy

Sanofi's post-reconstruction era

Lauren Martz, Senior Writer Five years after taking the helm as Sanofi 's president of global R&D, Elias Zerhouni is rounding out his strategy to revamp the division and rebuild the pipeline with the appointment...
BioCentury | Jun 9, 2016
Strategy

Sunrise in Paris

One component of Elias Zerhouni's multi-pronged strategy to access external innovation is the Sanofi-Sunrise initiative - a company-creation vehicle to accelerate translation of early stage technologies of strategic interest to the pharma. Launched in 2013, Sanofi-Sunrise...
BioCentury | Mar 17, 2016
Top Story

Sanofi, DiCE form discovery collaboration

...million in milestones per target, plus royalties. Sanofi said the deal is part of its Sanofi Sunrise...
BioCentury | Jan 18, 2016
Strategy

Warp's independence day

Stephen Hansen, Associate Editor New revelations about the breadth of Warp Drive Bio LLC's platform, coupled with the lengthy biotech boom, led the company and partner Sanofi to toss out their 2012 build-to-buy deal in...
Items per page:
1 - 7 of 7
BioCentury | Aug 13, 2020
Management Tracks

NHC’s Boutin to head patient advocacy at Novartis; plus changes at Moderna, PIC, Atea, Terns, NBE and Omega

...of R&D strategy at Sanofi (Euronext:SAN; NASDAQ:SNY), and also previously launched and led the pharma’s Sanofi Sunrise...
BioCentury | Apr 28, 2018
Strategy

The outsiders

As he retires from Sanofi, Elias Zerhouni has advice for the biopharma industry: the traditional executive mold must be expanded. On April 24, Sanofi announced Zerhouni would retire on June 30 and that John Reed,...
BioCentury | Aug 17, 2017
Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
BioCentury | Jun 9, 2016
Strategy

Sanofi's post-reconstruction era

Lauren Martz, Senior Writer Five years after taking the helm as Sanofi 's president of global R&D, Elias Zerhouni is rounding out his strategy to revamp the division and rebuild the pipeline with the appointment...
BioCentury | Jun 9, 2016
Strategy

Sunrise in Paris

One component of Elias Zerhouni's multi-pronged strategy to access external innovation is the Sanofi-Sunrise initiative - a company-creation vehicle to accelerate translation of early stage technologies of strategic interest to the pharma. Launched in 2013, Sanofi-Sunrise...
BioCentury | Mar 17, 2016
Top Story

Sanofi, DiCE form discovery collaboration

...million in milestones per target, plus royalties. Sanofi said the deal is part of its Sanofi Sunrise...
BioCentury | Jan 18, 2016
Strategy

Warp's independence day

Stephen Hansen, Associate Editor New revelations about the breadth of Warp Drive Bio LLC's platform, coupled with the lengthy biotech boom, led the company and partner Sanofi to toss out their 2012 build-to-buy deal in...
Items per page:
1 - 7 of 7